ISSN (Electrónico): 2590-5708
Formato: Electrónico / Acceso Abierto
Frecuencia: Números Anuales
Revisión por Pares: Doble Ciego
Keywords
Veterinary pharmacovigilance
veterinary medicine
adverse drug reactions
drug Residues
environment Farmacovigilancia veterinaria
medicina veterinaria
reacciones adversas
residuos de Medicamentos
ambiente
veterinary medicine
adverse drug reactions
drug Residues
environment Farmacovigilancia veterinaria
medicina veterinaria
reacciones adversas
residuos de Medicamentos
ambiente
How to Cite
Osorio Bedoya, E. J., & Rodríguez Montoya, V. (2023). Perspectives of veterinary pharmacovigilance in Colombia and the world: a structured review. Ciencia, Tecnología E Innovación En Salud, 7, 46–61. https://doi.org/10.23850/25393871.6125
Abstract
The Colombian Agricultural Institute defines veterinary pharmacovigilance as “the set of activities for the identification, evaluation and prevention of the risks of using veterinary drugs and biologics once they are marketed, and includes a continuous process of recording and evaluation of adverse events". The national pharmacovigilance program was created in 2017, while in the European Union and the United States, these programs have been around 30 years. The aim of this review was to identify the contributions found in the literature about veterinary pharmacovigilance and join the information on adverse events published to date, so that important information generated that contributes to improve veterinary pharmacovigilance in Colombia. Therefore, a structured review was carried out in Embase, PubMed, Scielo, Liliacs, Redalyc and Google Scholar, searching for terms such as “veterinary medicine”, “adverse drug reaction” and “pharmacovigilance”. 51 articles in English and Spanish were included, with full text access and published between 2000 and 2020. Veterinary pharmacovigilance publications were identified, which show that it is a field with great prospects and challenges, and it requires the implementation, maintenance and strengthening of veterinary pharmacovigilance programs in Colombia and the world. In addition, it is necessary to continue researching to generate more evidence to make the best decisions regarding the use and safety of these drugs.
References
Colmar C. Perspectives for applied pharmacology in veterinary pharmacovigilance. J. Vet. Pharmacol. Therap. (U.S.A.) 2015. 38, 1–81. doi.org/10.1111/jvp.12246
Barbero R, Cuniberti B, Barbarino G, Brizio G. Establishment of a regional centre of veterinary pharmacovigilance in piedmont analysis of early data. J. Vet. Pharmacol. Therap. (U.S.A.). 2009. (32): 129–265. doi.org/10.1111/j.1365-2885.2009.01091.x
European Medicines Agency (EMA). International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). World Wide Web electronic publication. 2020. Disponible desde internet en: https://www.ema.europa.eu/ (Con acceso el 25/11/2020)
Instituto Colombiana Agropecuario (ICA). Resolución 10204 de 2017 “Por medio de la cual se establece el Programa Nacional de Farmacovigilancia para medicamentos y biológicos de uso veterinario”. Bogotá, 2017.
Iragüen D, Urcelay B, San Martín B. Farmacovigilancia en medicina veterinaria: Una perspectiva desde el punto de vista internacional y situación actual en Chile. Archivos de Medicina Veterinaria 2007. 39: 195–206.
Bobkov M, Zbinden P. Occurrence of Veterinary Drug Residues in Poultry and Products Thereof. A Review. Food Analysis: Meat And Meat Products. CHIMIA International Journal for Chemistry. 2018. 72(10): 707–712. doi:10.2533/chimia.2018.707
Keck G. Veterinary pharmacovigilance in the European context. Annali Dell'istituto Superiore di Sanita (Francia) 1992. 28 (4): 425-428.
Iragüen D, Urcelay S, San Martin B. Pharmacovigilance in veterinary medicine in Chile: a pilot study. J. Vet. Pharmacol. Therap. 2010. 34: 108-115 doi:10.1111/j.1365-2885.2010.01201.x
Simpson A, Bradley C, Schissler J. Probable cutaneous adverse drug reaction due to a cannabidiol-containing hemp oil product in a dog. Veterinary Dermatology. 2020, 31(5):404-e108. doi.org/10.1111/vde.12876
Bataller N, Keller W. Monitoring adverse reactions to veterinary drugs. Pharmacovigilance. The Vet. Clinics of North America. Food Animal Practice. 1999 15(1): 13-30. doi.org/10.1016/S0749-0720(15)30204-8
Baynes R, Dedonder K, Kissell L, Mzyk D, Marmulak T, Smith G, Gehring R, Davis J, Riviere J. Health Concerns and Management of Select Veterinary Drug Residues. Food and Chemical Toxicology. 2016. 88:112-122. doi.org/10.1016/j.fct.2015.12.020.
Venable R, Haynes C, Cook J. Reported prevalence and quantitative LC-MS methods for the analysis of veterinary drug residues in honey: a review. Food Additives & Contaminants: Part A. 2014. 31(4):621–640. doi.org/10.1080/19440049.2014.886339
Quesada S, Paschoal J, Reyes F. Considerations on the aquaculture development and on the use of veterinary drugs: Special issue for fluoroquinolones-a review. Journal of Food Science. 2013, 78(9), 1321–1333. doi.org/10.1111/1750-3841.12222
Wang X, Martínez M, Aránzazu W, Qinghua A, Irma M, Larrañaga M, Anadón A, Yuan Z. Fipronil insecticide toxicology: oxidative stress and metabolism. Critical Reviews in Toxicology. 2016, 46(10): 876-899.doi:10.1080/10408444.2016.1223014
Sández I, Cabezas M. Manual clínico de farmacología y complicaciones en anestesia de pequeños animales. Ed. Multimédica. 2018. 272p.
Guzmán M, Buronfosse F, Fernández A. Revisión de casos de intoxicaciones agudas accidentales por calcipotriol y tacalcitol en perros en el CNITV (Francia) (1999-2003). Revista de Toxicología. 2004. 21(2–3): 81–86.
Jordan T, Affolter V, Outerbridge C, Goodale E, White S. Clinicopathological findings and clinical outcomes in 49 cases of feline pemphigus foliaceus examined in Northern California, USA (1987-2017). Veterinary Dermatology 2019. 1–11 doi:10.1111/vde.12731
Rochel D, Siliart B, Friol A, Jaillardon L. Trilostane drug safety surveillance: a retrospective study of 103 cases. J. Vet. Pharmacol. Therap. 2015. 38, 1–81. doi.org/10.1111/jvp.12246
Mellor P, Roulois A, Day M, Blacklaws B, Knivett S, Herrtage M. Neutrophilic dermatitis and immunemediated haematological disorders in a dog: suspected adverse reaction to carprofen. J. of Small Animal Practice. 2005 46(5): 237–242. doi.org/10.1111/j.1748-5827.2005.tb00316.x
Combes R. Is phenylbutazone a genotoxic carcinogen? A weight-of-evidence assessment. Alternatives to Laboratory Animals. 2013, 41(3): 235–248. doi.org/10.1177/026119291304100307
Ogada D, Keesing F, Virani M. Dropping dead: Causes and consequences of vulture population declines worldwide. Annals of the N.Y. Academy of Sciences. 2012, 1249(1): 57–71. doi.org/10.1111/j.1749-6632.2011.06293.x
Hutchinson T, Madden J, Naidoo V, Walker C. Comparative metabolism as a key driver of wildlife species sensitivity to human and veterinary pharmaceuticals. Philosophical Transactions of the Royal Society B: Biological Sciences. 2014, 369 (1656). doi.org/10.1098/rstb.2013.0583
Naidoo V. Overview of suspected adverse reactions to veterinary medicinal products reported in South Africa (March 2003 - February 2004). Journal of the South African Veterinary Association. 2003 74(4): 137–140. doi:10.4102/jsava.v74i4.528
Woodward K. Veterinary pharmacovigilance. Part 2. Veterinary pharmacovigilance in practice - the operation of a spontaneous reporting scheme in a European Union country - the UK, and schemes in other countries. J. Vet. Pharmacol. Therap. 2005. 28(2): 149–170. doi.org/10.1111/j.1365-2885.2005.00646.x
Mouiche M, Njingou B, Moffo F, Mpouam S, Feussom J, Awah-Ndukum J. Veterinary pharmacovigilance in sub-Sahara Africa context: A pilot study of adverse reactions to veterinary medicine in Cameroon. BMC Veterinary Research. 2009. 15(1): 301. doi.org/10.1186/s12917-019-2043-1
Merola V, Khan S, Gwaltney-Brant S. Ivermectin toxicosis in dogs: A retrospective study. Journal of the American Animal Hospital Association 2009, 45(3): 106–111. doi.org/10.5326/0450106
Ortelli D, Spörri AS, Edder P. Veterinary drug residue in food of animal origin in Switzerland: A health concern? Chimia, 2018 72(10): 713–717. doi.org/10.2533/chimia.2018.713
Buronfosse-Roque F, Hercberg-Rebelle B, Queffélec S, Pérez M, Pineau X. Posible tratamiento con lípidos intravenosos de carnívoros domésticos intoxicados con lactonas macrocíclicas. Revista de Toxicología 2012, 29(1):40-44.
Lozano A, Arias D. Residuos de fármacos en alimentos de origen animal: panorama actual en Colombia. Revista Colombiana de Ciencias Pecuarias. 2008. (21): 121-135.
Li P, Wu Y, Wang Y, Qiu J, Li Y. Soil Behaviour of the Veterinary Drugs Lincomycin, Monensin, and Roxarsone and Their Toxicity on Environmental Organisms. Molecules, 2019 24(24): 4465. doi.org/10.3390/molecules24244465
Rusch M, Spielmeyer A, Zorn H, Hamscher G. Degradation and transformation of fluoroquinolones by microorganisms with special emphasis on ciprofloxacin. Applied Microbiology and Biotechnology. 2019 103:6933–6948. doi.org/10.1007/s00253-019-10017-8
Komarov A, Yunin P, Metalnikov S, Panin A. Development of confirmatory method for analysis of (beta)-agonists in various matrices. J. Vet. Pharmacol. Therap. 2012. 35: 78–102. doi.org/10.1111/jvp.12005
San Martin B, Kruze J, Morales M, Agüero H, Leon B, Esppinoza S, Borie C. Resistencia bacteriana en cepas patógenas aisladas de mastitis en vacas lecheras de la V Región, Región Metropolitana y Xa Región, Chile. Archivos de Medicina Veterinaria. 2002 34(2): 221–234.
Chiarlone C, Colmar C, Renaud A, Cadiergues M. Encouraging reporting in the veterinary profession: Prospective study and analysis of the pharmacovigilance system in university settings. Revue Veterinaire Clinique. 2016 51(1): 23–34. doi.org/10.1016/j.anicom.2016.02.001
Ghadevaru S. Veterinary pharmacovigilance-a pilot study in Tamil Nadu, India. Drug Safety. 2013 36(9): 793–951. doi.org/10.1007/s40264-013-0087-x
Woodward K. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union. J. Vet. Pharmacol. Therap. 2005 28:131–147. doi.org/10.1111/j.1365-2885.2005.00645.x
Keck G, Ibrahim C. Veterinary pharmacovigilance: between regulation and science. J. Vet. Pharmacol. Therap. 2001 24: 369–373. doi.org/10.1046/j.1365-2885.2001.00375.x
Linnett P, Dagg P. The veterinary pharmacovigilance program of the APVMA. Australian Veterinary Journal. 2005 83: 32–37. doi.org/10.1111/j.1751-0813.2005.tb12188.x
Kumar R, Kalaiselvan V, Verma R, Kaur I, Kumar P, Singh G. Veterinary pharmacovigilance in India: A need of hour. Indian Journal of Pharmacology. 2017 49:2–3. doi.org/10.4103/0253-7613.201035
De Briyne N, Gopal R, Diesel G, Iatridou D, O’rourke D. Veterinary pharmacovigilance in Europe: A survey of veterinary practitioners. Veterinary Record Open. 2017 4(1). doi.org/10.1136/vetreco-2017-000224
García B, Hernández D, Soler F, Pérez-López M. Empleo de Ivermectina como parasiticida en ovino: posibles efectos tóxicos y repercusiones ambientales. Anales de Veterinaria de Murcia. 2001, 27(0): 23–32. doi.org/10.6018/j/160111
Astaiza J, Benavides C, Muñoz G, Mora M, Cháves C. Principales hábitos de medicación por los propietarios de caninos que acuden a consulta veterinaria en Pasto, Nariño, Colombia. Rev. Colombiana de Ciencias Químico-Farmacéuticas. 2016 45 (1): 92–108. doi.org/10.15446/rcciquifa.v45n1.58019
Hunt J, Dean R, Davis G, Murrell J. An analysis of the relative frequencies of reported adverse events associated with NSAID administration in dogs and cats in the United Kingdom. Veterinary Journal 2015 206(2): 183–190. doi.org/10.1016/j.tvjl.2015.07.025
Mcgrath S, Bartner L, Rao S, Packer R, Gustafson D. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019 254(11):1301–8. 10.2460 / javma.254.11.1301
Martello E, Bigliati M, Bisanzio D, Biasibetti E, Dosio F y Pastorino D. Effects on pain and mobility of a new diet supplement in dogs with osteoarthritis: a pilot study. Ann Clin Lab Res. 2019 7:304. doi: 10.21767/2386-5180.100304
Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. The Veterinary Journal, Volume 173, Issue 1,
, Pages 21-30. doi.org/10.1016/j.tvjl.2005.10.003
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 15:270–8. doi: 10.1016/S1474-4422(15)00379-8
Tambaro S y Bortolato M. Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov. (2012) 7:25–40. doi: 10.2174/157488912798842269
Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019 23:18–041. doi: 10.7812/TPP/18-041
Hidalgo R. Papel del farmacéutico en la venta y distribución de medicamentos veterinarios. An Real Acad Farm Año 2020. Volumen 86 Número 1. pp. 75 - 88 doi.org/10.53519/analesranf.2020.86.01.06
Instituto Colombiana Agropecuario (ICA). Buenas Prácticas en el uso de medicamentos veterinarios y la inocuidad de los alimentos. Grupo Transferencia de Tecnología. Segunda edición. Bogotá, 2007
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Servicio Nacional de Aprendizaje (SENA)
Downloads
Download data is not yet available.
